To investigate the therapeutic promise of EphA4 synthetic agonists in additional ALS backgrounds we utilized a rapid reprogramming method that generates neuronal progenitor cells (NPC) directly from patient fibroblasts. This evidence concerns the gene EPHA4 and amyotrophic lateral sclerosis.